INTRODUCTION
Psoriasis is a common inflammatory skin disease with a complex genetic background (Nair et al., 2009; Nestle et al., 2009; Strange et al., 2010) , and it affects 2-3% of the Caucasian population . The aim of this study was to compare profiles of known psoriasis-associated genetic variants between patients with a severe and mild disease course focusing on the skin phenotype. How to define disease severity is not trivial even when only considering skin involvement, but the psoriasis area severity index (PASI) is commonly used for grading (Fredriksson and Pettersson, 1978) . Obviously, PASI is a subjective measure, and scores will vary over time in the individual patient and most importantly will reflect ongoing treatments. A more functional approach was applied in the present study. The disease was considered severe when requiring systemic therapy and mild when only topical or no treatment was applied/indicated. All patients were examined and treated at the same department with long-term follow-up ensuring a reasonable consistency in assessment.
The genetic contribution to disease is extensive with HLA-C*06 showing the most significant association (Nair et al., 2000) , although genome-wide association studies have identified another 35 psoriasis risk regions presented at ImmunoBase (http://www.immunobase.org/). The majority of susceptibility genes are involved in the immune system and in pathways that clearly have a role in the pathophysiology of psoriasis. Thus, drugs targeting these pathways show impressive efficacy in controlling psoriasis inflammation, and their in vivo relevance has convincingly been validated (Cargill et al., 2007; de Cid et al., 2009; Ellinghaus et al., 2010; Huffmeier et al., 2010; Strange et al., 2010; Tsoi et al., 2012) . Psoriasis inflammation arises through combined innate and adaptive immune responses (Dempsey et al., 2003) , and in this process T cells are important factors regulating the cross-talk between the immune system and the skin (Nair et al., 2009) . In recent years, researchers have focused on the pathological IL23/IL17/ IL22 axis, where data from genetic, experimental, and clinical research seem to converge (Di Cesare et al., 2009 ).
IL-23 has a crucial role in the development of pathogenic Th17 cells and induces inflammation (Aggarwal et al., 2003; Bettelli et al., 2006) . Other genes that also have a role in the psoriasis-associated IL-23 signaling pathway are IL21, STAT3, and TYK2 (Andres et al., 2013; Caruso et al., 2009b; Ellinghaus et al., 2012) , and, it has been shown that IL21 and STAT3 are upregulated in psoriasis lesions (Andres et al., 2013; Caruso et al., 2009b) , whereas Tyk2 is downregulated (Andres et al., 2013) . IL-13 is produced mainly by Th2 cells and has been associated with psoriasis arthritis (PsA) (Eder et al., 2011) , and IL-21 is produced by Th17 cells and has shown association with psoriasis (Yin et al., 2014) .
Nuclear factor-kappa B (NF-κB)/Rel transcription factors have a critical role in regulating the expression of many cytokines involved in the pathogenesis of psoriasis (Baeuerle and Baltimore, 1996; Baldwin, 1996; Barnes and Karin, 1997) . NF-κB is composed of homo-or heterodimers of Rel and NF-κB proteins (Baeuerle and Baltimore, 1996) . NF-κB complexes are held in the cytoplasm in an inactive state bound to members of the NF-κB inhibitor (NFKBI) family such as NFKBIA and NFKBIL1. Tumor necrosis factor alpha (TNFA) is a multifunctional proinflammatory cytokine that stimulates NF-κB activity. Other proteins involved in regulating NF-κB activation are TNFA-induced protein 3 (TNFAIP3), TNFAIP3interacting protein 1 (TNIP1), and TRAF3-interacting protein 2 (TRAF3IP2). Dysregulation of the NF-κB system is thought to be central in inflammatory and stress responses.
Psoriasis shows large clinical variation, but few studies have explored the genetic profiles, apart from HLA-C*06, in stratified phenotypes (Fan et al., 2007; Zheng et al., 2010; Julià et al., 2012; Lysell et al., 2013) . With the exception for generalized pustular psoriasis (Marrakchi et al., 2011; Onoufriadis et al., 2011) , most genetic studies have analyzed a mixture of clinical subtypes and thus revealed psoriasis risk genes shared by the majority of phenotypes. However, when using carefully phenotyped psoriasis cohorts, genetic exploration will likely reveal new risk variants. Stratification of phenotypes can be performed in many ways: age of disease onset, severity, presence of comorbidities, and family history just to mention a few. In the current study, we have compared the association of known genetic risk factors focusing on the IL-23 and NF-κB pathways between two polarized cohorts of psoriasis individuals, those with consistently mild psoriasis who have not required systemic therapy for at least 6-14 years disease course but been treated only topically or not at all, and severe psoriasis requiring systemic therapy. Our study reveals that association of these susceptibility genes is restricted to the severe psoriasis skin phenotype.
RESULTS
Genetic association with IL23R, NFKB1, IL21, IL12B, NFKBIL1, and IL23A was confined to psoriasis cases with severe skin phenotype
The samples analyzed are shown in Table 1 where basic indicators such as age at onset, disease duration, BMI, and psoriasis nail involvement are presented. PASI values are calculated after 6-14 years disease in the mild cohort and at inclusion in the severe cohort. Only few patients were without therapy or with short wash-out after previous treatments when included in the latter registry. Still, the data show significant differences between the cohorts.
Genotypes and minor allele frequencies of the examined gene variants are shown in Table 2 . In addition to HLA-C*06, we found strong association with TRAF3IP2 (rs33980500-T), TNFAIP3 (rs610604-C), STAT3 (rs9912773-G), TNF (rs1800629-G), IL23A (rs2066808-A), and IL12B (rs285394-G) in all psoriasis subjects (Table 2) , with all P-values remaining significant after correction for multiple testing (Po0.05). We also found significant association with IL12B (rs10045431-A), NFKBIL1 (rs2255798-G), as well as for IL13 (rs20541-C), TNIP1 (rs3762999-G), TYK2 (rs12720356-T), and IL12RB1 (rs401502-C), for all psoriasis subjects (Table 2 ) but with only association with TYK2 remaining significant after multiple testing (Po0.05). Intriguingly, when analyzing severe versus control and mild versus control, the association for IL12B (rs10045431-A), NFKBIL1 (rs2255798-G), and IL23A (rs2066808-A) disappeared for the mild clinical phenotype and increased or remained the same in the severe phenotype (Table 3) . When analyzing severe versus mild phenotypes in a case-case study, the common allele for IL23R (rs7530511), IL21 (rs2221903), IL12B (rs3212227), and IL23A (rs2066808) showed association with the severe phenotype, whereas for IL23R (rs2201841), NFKB1 (rs2293970), IL12B (rs10045431), and NFKBIL1 (rs2255798) the minor allele showed association with risk to the severe phenotype ( Figure 1 and Table 3 ). Both SNPs in IL23R (rs7530511 and rs2201841) as well as NFKBIL1 (rs2255798) and IL23A (rs2066808) remained significant after multiple testing (Po0.05). No association for REL and NFKBIA was observed for either phenotype. We observed no deviation from Hardy-Weinberg equilibrium for any of the markers (P40.05), and duplicates did not reveal any genotyping errors.
Haplotype analysis for the IL23R and IL12B genes significantly increased association with psoriasis cases with severe disease Haplotype association, with at least one risk allele present for both SNPs in the IL23R gene, increased the association odds ratio (OR) to 1.55 (P = 0.003, 95% confidence interval (CI) Table S1 online) in the severe disease cohort. Two IL12B haplotypes were associated with severe psoriasis ( Supplementary Table S1 online). The strongest association was seen for the haplotype with at least one risk allele present for all three SNPs in the IL12B gene (P = 9 × 10 -6 , OR 1.64; 95% CI: 1.30-2.07). Interestingly, the OR increased to 2.19 (P = 0.005, 95% CI 1.40-3.41), with two risk alleles present for all variations of the IL12B gene ( Supplementary Table S1 online). In addition, we performed a χ 2 -test for trend, which for the allelic haplotype in IL23R showed χ 2 = 16.07 (Po0.00006), for the allelic haplotype in IL12B showed χ 2 = 22.58 (Po0.00001), and for the genotypic haplotype in IL12B showed χ 2 = 15.51 (Po0.00008) ( Supplementary Table S1 online). All P-values remained significant after multiple testing (Po0.05).
Interaction between genes within and between the IL-23 and NF-κB pathways
To analyze interaction, we selected ten genes, IL23R, NFKB1, TNIP1, IL12B, HLA-C, NFKBIL1, TNF, TRAF3IP2, IL23A, and STAT3, to be analyzed against all other sixteen genes. In the severe psoriasis phenotype, we observed biological interaction on the additive scale between genes in the two different pathways: TNFAIP3 and NFKBIL1 (APp 0.02, AP 0.297 (0.049-0.545), P = 5 × 10 − 7 , OR 2.02; 95% CI: 1.54-2.66) (Figure 2a and Supplementary Table S2 online) and TNIP1 and IL23R (APp 0.04, AP 0.275 (0.007-0.543), P = 1 × 10 − 6 , OR 2.01; 95% CI: 1.51-2.66) ( Supplementary Table S2 online). The most significant interaction was found between TNIP1 and NFKBIL1 (APp 0.000001, AP 0.503 (0.301-0.705), P = 1 × 10 − 8 , OR 2.58; 95% CI: 1.86-3.58) (Figure 2b and Supplementary Table S2 online). In the severe psoriasis phenotype, we also observed an interaction on the additive scale between the HLA-C risk allele and five other genes risk alleles: IL23R (Figure 2c ), NFKB1 (Figure 2d ), TNIP1, IL12B, and IL23A ( Supplementary Table S2 online). No interaction was observed in the mild disease group. The two most significantly associated interactions remained significant after correction: TNIP1 and NFKBIL1 as well as HLA-C and NFKB1 (Po0.05). Contemplates OR for the minor allele.
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DISCUSSION
This study describes association with genes in the IL-23 and NF-κB pathways in carefully characterized Swedish psoriasis cohorts stratified by severity of the skin phenotype. Several studies have previously highlighted the importance of genes and haplotypes in both the IL-23 and NF-κB pathways in psoriasis ( PsA (Cargill et al., 2007; Capon et al., 2007; Liu et al., 2008; Nair et al., 2010; Franke et al., 2010; Strange et al., 2010; Bowes et al., 2011; Wang et al., 2012; Di Meglio et al., 2013; Popa et al., 2013; Eiris et al., 2014) , Crohn's disease (Chua et al., 2012; Dinu et al., 2012; Jung et al., 2012) , inflammatory bowel disease (Duerr et al., 2006; Safrany et al., 2013) , ankylosing spondylitis (Safrany et al., 2009) , celiac disease, and multiple sclerosis (Nunez et al., 2008) . The present study revealed that eight SNPs in six of the studied genes associate with psoriasis with a severe phenotype, whereas no association was found in patients with a consistent mild phenotype (Figure 1 ). There are several measures to assess clinical severity in psoriasis skin disease such as, PASI, body surface area, psoriasis global assessment, and patient's global assessment. There is no ultimate measure but the most commonly used is PASI, which works reasonably well at a given time point. However, our aim was to study longterm disease course, and we have access to a unique group of patients with long-term follow-up, thus ensuring a confident phenotype over time. In this study, the definition of mild psoriasis was patients who had not received, nor been eligible for systemic therapy up to 14 years following onset. Severe psoriasis was defined as treatment with systemic therapy indicated by psoriasis skin disease. In a substantial proportion of patients with severe psoriasis, the baseline PASI scores were not available. Therefore, defining severity based on treatment is in our opinion functionally relevant. Only three dermatologists in close collaboration in the same department have treated these patients; hence, we feel confident that the assessment is harmonized. The aim was to study specifically psoriasis skin disease, and to optimize the stratification we have not included assessment of PsA. The psoriasis population primarily treated in dermatology differs from the PsA population in rheumatology; thus, our patients do not represent the complete PsA phenotype.
HLA-C*06 is without question the strongest associated gene in psoriasis. Interestingly, this still holds true when stratified by severity and HLA-C*06 was equally associated in the severe and mild cohorts with no statistical difference between the groups.
Herein we show that association with five SNPs within the IL23R, IL23A, and IL12B genes is confined to the severe psoriasis phenotype. IL-23 has a crucial role in the development of pathogenic Th17 cells and is critically involved in autoimmune inflammatory diseases (Aggarwal et al., 2003; Bettelli et al., 2006) . Knockout mice deficient for IL-23, for either p40 or p19, or for either subunit of the IL-23 receptor develop less severe symptoms of multiple sclerosis and inflammatory bowel disease emphasizing the general importance of IL-23 in inflammation (Langowski et al., 2006; Kikly et al., 2006) , and therapy blocking the p40 subunit shared between IL-23 and IL-12 shows impressive clinical efficacy in psoriasis (Leonardi et al., 2008) .
NFKBIL1 also showed association confined to the severe phenotype of psoriasis. NFKBIL1 is important in the regulation of the NF-κB pathway and has been implicated in the pathogenesis of rheumatoid arthritis, ulcerative colitis (association with the severe type), and systemic lupus erythematosus (De La Concha et al., 2000; Greetham et al., 2007; Cen et al., 2013) but has not previously been reported in psoriasis. In our material, there was no association with NFKB1 in the whole material, but a significant difference between the groups was detected when stratifying for severity. This is in line with published data reporting association with NFKB1 in severe psoriasis with PASI 420 (Li et al., 2008) . Similarly, there was no association with IL21 in the combined cohorts, but after stratification the severe group showed association, indicating an effect on disease severity from IL-21. IL-21 is produced by activated CD4 + T cells (among others) and has an important regulatory role in the immune system. Caruso et al., 2009b have shown a role for IL-21 in promoting epidermal hyperplasia and expanding pathogenic Th-cell responses in psoriasis (Caruso et al., 2009b) . The SNP rs12720356-T allele in TYK2 showed association in the whole psoriasis group, but after stratification the association remained only in the severe group and disappeared in the mild group. Although we cannot show a significant difference between the groups, this is still intriguing as TYK2 is part of the IL-23 pathway, which seems preferentially involved in the severe psoriasis phenotype, and inhibition of Tyk2 kinase activity led to significantly reduced IL-23-induced skin inflammation and may be an effective therapeutic strategy for the treatment of psoriasis (Liang et al., 2013; Ishizaki et al., 2014) .
For the entire psoriasis cohort, there were significant associations for STAT3, TNF, TNFAIP3, and TRAF3IP2 but with no significant difference when stratified by severity, indicating their overall involvement.
Significant research is devoted to the detection and investigation of interaction between genes. For complex traits, gene interaction has become a hot topic. Thus, in the presence of interaction, where the effect of one locus is altered or masked by the effect of another locus, the power to detect the first locus may be reduced. Even though HLA-C*06 associates equally strong in both cohorts, interaction between HLA-C*06 and risk alleles in IL23R, NFKB1, TNIP1, IL12B, and IL23A (Supplementary Table S2 online) was restricted to the severe phenotype. TNIP1 also interacted with IL23A and NFKBIL1, whereas NFKBIL1 also interacted with STAT3 only in the severe cohort.
Finally, in a haplotype analysis of the severe phenotype, an even stronger association could be shown for IL23R and IL12B when considering more than one risk allele ( Supplementary  Table S1 online).
Taken together, the data presented here show the importance of careful phenotyping and long-term follow-up of clinical materials. This may be cumbersome and difficult to achieve but is likely rewarding in understanding the genetic complexity and will pave the way for effective personalized medicine. In addition, it is important to study the combinations of SNPs, and not only the individual SNPs, as some polymorphisms tend to act only in specific blocks and may be overlooked otherwise.
MATERIALS AND METHODS

Samples
The analyses were carried out on 1,411 psoriasis patients of Caucasian ethnicity (781 males and 630 females; average age of onset 33.8 years; range 1-84 years) and 1,529 ethnically matched controls (723 males and 806 females; age not known) ( Table 1) . All patients included in the study were examined and the diagnosis of psoriasis verified by only three different dermatologists at the department of Dermatology, Karolinska University Hospital, Stockholm, Sweden. For inclusion, patients needed to present with at least one typical psoriasis lesion at the time for examination. Scalp involvement only was not regarded as diagnostic. Patients who had needed only topical treatment during the 6-to 10-year follow-up period were diagnosed with mild psoriasis, whereas patients who needed systemic treatment were diagnosed with severe psoriasis. The severe group had a disease duration up to 26 years and was followed for a minimum 6 years. The study was approved by the Regional Committee of Ethics and performed according to the Declaration of Helsinki Principles. Healthy controls were recruited at the dermatology (n = 507) clinic at the Karolinska University Hospital and as blood donors at the Karolinska University hospital (n = 1,022). Patients and controls provided written informed consent, and, for children below 18 years of age, parental written consent was obtained. Only cases and controls of Caucasian origin based on ethnicity SNP genotyping were included (Giardina et al., 2008) .
Genotyping
Peripheral blood samples were collected and genomic DNA extracted by standard procedures. The genes included in our present study were genes previously reported to be associated with psoriasis at ImmunoBase (http://www.immunobase.org/) and that were confirmed to be involved in the IL-23 and NF-κB signaling pathway according to GeneCards (http://www.genecards.org/) and PathCard alpha (http:// pathcards.genecards.org/). The selection of SNPs included in our study was based on published data, and priority was given to SNPs previously reported to be associated with psoriasis. All SNPs were genotyped on the ABI PRISM 7900HT Fast Real-Time PCR System Instrument by using allele specific Taqman MGB probes labeled with fluorescent dyes FAM and VIC (Applied Biosystems, Foster City, CA, USA), according to the manufacturer's protocols. Allelic discrimination was made with the ABI PRISM 7900HT SDS and the SDS 2.2.1 program (Applied Biosystems). Genotyping success rates exceeded 99% for all SNPs in the total sample set. Ten percent of the samples were run as duplicates to check for genotyping errors. HLA-C*06:02 typing was carried out as previously described by Nikamo et.al. (Nikamo and Ståhle, 2012) .
Statistical analysis
Case-control analysis was performed to test association with psoriasis comparing with population controls. Case-case analysis was used to compare severe and mild phenotypes. Both case-control and the case-case analyses were tested for allele frequency differences for all SNPs using logistic regression with gender and age as covariates. Associations between genetic markers and disease status were analyzed using the PLINK v1.07 (Purcell et al., 2007) . The potential interaction between genes was examined by calculation of departure from additivity of effects and evaluated by calculating attributable proportion (AP) due to interaction, as suggested by Rothman, together with a 95% CI, using the R program v 2.15.0 with GLM (http://www. r-project.org/). Haplotypes were analyzed using the R program v 2.15.0 with GLM (http://www.r-project.org/). For the Trend test, we used χ 2 for trend by the extended Mantel-Haenszel, as implemented in StatCalc, Epi info 7.1.3.0 (http://wwwn.cdc.gov/epiinfo/7/index.htm). For both haplotype and Trend test score zero was used for the reference haplotype in which no risk alleles were present; increasing score numbers were then used for increasing number of risk alleles, considering both hetero-and homozygotes. Hardy-Weinberg equilibrium was evaluated for each SNP using a χ 2 -test.
We have highlighted P-values that would remain significant after correction for multiple testing using the adjust mode as implemented in PLINK v1.07 (Purcell et al., 2007) (Table 2 ). In data presented in Table 3 , we have adjusted for stratification into two cohorts; mild and severe, using the Sidák correction (Sidák, 1967) , where P-values are adjusted using simple functions of the number of tested hypotheses. For haplotype analysis Sidák correction was also used to adjust for multiple testing, two comparisons for IL23R and five comparisons for IL12B. Sidák correction was also used to adjust for multiple testing in the interaction analysis, where 10 genes were selected and compared against all other sixteen genes, thus resulting in 160 tests.
